DNX-2401: an investigational drug for the treatment of recurrent glioblastoma

References

• Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009 Aug;18(8):1061–1083. PubMed PMID: 19555299.
   PubMed Web of Science ®Google Scholar
• Kang JH, Adamson C. Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opin Investig Drugs. 2015;24(10):1361–1379. . PubMed PMID: 26289791.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996. PubMed PMID: 15758009.
   PubMed Web of Science ®Google Scholar
• Babu R, Komisarow JM, Agarwal VJ, et al. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. 2016 Apr;124(4):998–1007. PubMed PMID: 26452121.
   PubMed Web of Science ®Google Scholar
• Li J, Di C, Mattox AK, et al. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med. 2010;3:111–127. PubMed PMID: 23226047; PubMed Central PMCID: PMCPMC3513213.
   PubMedGoogle Scholar
• Kanu OO, Hughes B, Di C, et al. Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol. 2009 Apr 8;3:39–52. PubMed PMID: 19777070; PubMed Central PMCID: PMCPMC2748278.
   PubMedGoogle Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016 Sep 01;3(3):198–210.
   PubMed Web of Science ®Google Scholar
• Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol. 2013 Jan;15(1):4–27. PubMed PMID: 23136223; PubMed Central PMCID: PMCPMC3534423.
   PubMed Web of Science ®Google Scholar
• Babu R, Adamson DC. Fluorescence-guided malignant glioma resections. Curr Drug Discov Technol. 2012 Dec;9(4):256–267. PubMed PMID: 22339071.
   PubMedGoogle Scholar
• de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014 Apr;16(4):380. . PubMed PMID: 24510742.
   PubMed Web of Science ®Google Scholar
• Stepanenko AA, Chekhonin VP. Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: a glimmer of hope in the search for an effective therapy? Cancers (Basel). 2018 Dec 5;10(12). DOI:10.3390/cancers10120492. PubMed PMID: 30563098; PubMed Central PMCID: PMCPMC6316815.
   PubMed Web of Science ®Google Scholar
• Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical phase III trials. Crit Rev Oncol Hematol. 2013 Sep;87(3):265–282. PubMed PMID: 23453191.
   PubMed Web of Science ®Google Scholar
• Dos Santos MA, Pignon JP, Blanchard P, et al. Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. J Neurooncol. 2015 Jun;123(2):307–314. PubMed PMID: 25975195.
   PubMed Web of Science ®Google Scholar
• Su J, Cai M, Li W, et al. Molecularly targeted drugs plus radiotherapy and temozolomide treatment for newly diagnosed glioblastoma: a meta-analysis and systematic review. Oncol Res. 2016;24(2):117–128. PubMed PMID: 27296952.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733–4740. PubMed PMID: 19720927.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709–722. PubMed PMID: 24552318.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699–708. PubMed PMID: 24552317; PubMed Central PMCID: PMCPMC4201043.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Nassiri F, Wang J, et al. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? Neuro Oncol. 2019 Jan 1;21(1):14–25. PubMed PMID: 30346600; PubMed Central PMCID: PMCPMC6303472.
   PubMed Web of Science ®Google Scholar
• Philbrick BD, Adamson DC. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. Expert Opin Investig Drugs. 2019 Mar;28(3):207–216. . PubMed PMID: 30676111.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003 May 7;95(9):652–660. PubMed PMID: 12734316.
   PubMed Web of Science ®Google Scholar
• Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001 Jun 1;15(11):1311–1333. PubMed PMID: 11390353.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gomez-Manzano C, Lang FF, et al. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009 Oct;9(5):422–427. PubMed PMID: 19860656; PubMed Central PMCID: PMCPMC2935304
   PubMed Web of Science ®Google Scholar
• Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta. 2002 May 3;1575(1–3):1–14. PubMed PMID: 12020813.
   PubMedGoogle Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997 Feb 28;275(5304):1320–1323. PubMed PMID: 9036860.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 1995 Mar;13(3):265–270. PubMed PMID: 9634769.
   PubMedGoogle Scholar
• Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001 Aug;49(2):380–389 discussion 390. . PubMed PMID: 11504114.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007 Sep 19;99(18):1410–1414. PubMed PMID: 17848677.
   PubMed Web of Science ®Google Scholar
• Jiang H, Clise-Dwyer K, Ruisaard KE, et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014;9(5):e97407. PubMed PMID: 24827739; PubMed Central PMCID: PMCPMC4020829.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005 Apr;5(4):275–284. PubMed PMID: 15803154.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 7;444(7120):756–760. PubMed PMID: 17051156.
   PubMed Web of Science ®Google Scholar
• Jiang H, White EJ, Gomez-Manzano C, et al. Adenovirus’s last trick: you say lysis, we say autophagy. Autophagy. 2008 Jan;4(1):118–120. PubMed PMID: 18032923.
   PubMed Web of Science ®Google Scholar
• Klein SR, Piya S, Lu Z, et al. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene. 2015 Oct 8;34(41):5295–5301. PubMed PMID: 25619840; PubMed Central PMCID: PMCPMC4515398.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Morales A, Zabaleta A, Guruceaga E, et al. Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection. Oncotarget. 2018 Jul 24;9(57):31045–31065. PubMed PMID: 30123426; PubMed Central PMCID: PMCPMC6089549.
   PubMedGoogle Scholar
• Gonzalez-Morales A, Zabaleta A, Garcia-Moure M, et al. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy. J Proteomics. 2019 Mar;1(194):168–178. PubMed PMID: 30503830.
   PubMed Web of Science ®Google Scholar
• Alonso MM, Gomez-Manzano C, Bekele BN, et al. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15;67(24):11499–11504. PubMed PMID: 18089777.
   PubMed Web of Science ®Google Scholar
• Jiang H, White EJ, Rios-Vicil CI, et al. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol. 2011 May;85(10):4720–4729. PubMed PMID: 21367888; PubMed Central PMCID: PMCPMC3126198.
   PubMed Web of Science ®Google Scholar
• Jiang H, Rivera-Molina Y, Gomez-Manzano C, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017 Jul 15;77(14):3894–3907. PubMed PMID: 28566332; PubMed Central PMCID: PMCPMC5549681.
   PubMed Web of Science ®Google Scholar
• Traylor JI, Kuo JS. Delta-24-RGD adenoviral therapy directs oncolytic and immune-mediated anti-tumor effects in recurrent malignant glioma patients. Neurosurgery. 2019 Jan 1;84(1):E11–E12. . PubMed PMID: 30395338.
   PubMed Web of Science ®Google Scholar
• Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013 Nov;13(11):777–789. PubMed PMID: 24113868; PubMed Central PMCID: PMCPMC6290922.
   PubMed Web of Science ®Google Scholar
• Alonso MM, Jiang H, Yokoyama T, et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther. 2008 Mar;16(3):487–493. PubMed PMID: 18253154.
   PubMed Web of Science ®Google Scholar
• Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005 Apr;16(4):525–537. PubMed PMID: 15728109.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018 May 10;36(14):1419–1427. PubMed PMID: 29432077; PubMed Central PMCID: PMCPMC6075856.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015 Sep;14(9):642–662. PubMed PMID: 26323545.
   PubMed Web of Science ®Google Scholar